Chemical Structure : YP200
Catalog No.: PC-28791Not For Human Use, Lab Use Only.
YP200 is a potent and isoform-selective HDAC11 inhibitor with IC50 of 58 nM, >103-fold selectivity over HDAC6 and no significant inhibitory activity against other classical HDACs.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
YP200 is a potent and isoform-selective HDAC11 inhibitor with IC50 of 58 nM, >103-fold selectivity over HDAC6 and no significant inhibitory activity against other classical HDACs.
YP200 treatment (0.2-20 uM) induced a dose-dependent accumulation of SHMT2 protein in HEK 293T cells, does not affect the levels of acetylated α-tubulin (HDAC6 substrate) and acetylated histone H3 (class I HDACs substrate) in NSCLC cells.
YP200 displayed potent and broad-spectrum anti-proliferative effects against a panel of human non-small cell lung cancer (NSCLC) cell lines: A549, PC-9, HCC827, and NCI-H1299 with IC50 of 7.12 uM, 8.45 uM, 3.14 uM, and 3.82 uM.
YP200 exerts anti-lung cancer activity by simultaneously blocking cell cycle progression and activating apoptotic pathways.
YP200 (25 and 50 mg/kg) exhibied anti-tumor efficacy in non-small cell lung cancer PDX model (PDX-LC-00144) in immunodeficient NOD/SCID mice.
YP200 inhibits the expression of Ki67 and Cyclin D1 in subcutaneous tumor tissues.
| M.Wt | 530.67 | |
| Formula | C31H38N4O4 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Yang X, et al. J Med Chem. 2026 Nov 12;69(21):25236-25255.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright